The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. 1995

M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitro cause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death, and that its protective action is even more striking in vivo than in vitro.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015194 Diffusion Chambers, Culture Devices used in a technique by which cells or tissues are grown in vitro or, by implantation, in vivo within chambers permeable to diffusion of solutes across the chamber walls. The chambers are used for studies of drug effects, osmotic responses, cytogenic and immunologic phenomena, metabolism, etc., and include tissue cages. Culture Diffusion Chambers,Semi-Permeable Chambers,Tissue Cages,Semipermeable Chambers,Cage, Tissue,Cages, Tissue,Chamber, Culture Diffusion,Chamber, Semi-Permeable,Chamber, Semipermeable,Chambers, Culture Diffusion,Chambers, Semi-Permeable,Chambers, Semipermeable,Culture Diffusion Chamber,Diffusion Chamber, Culture,Semi Permeable Chambers,Semi-Permeable Chamber,Semipermeable Chamber,Tissue Cage
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D016475 3T3 Cells Cell lines whose original growing procedure consisted being transferred (T) every 3 days and plated at 300,000 cells per plate (J Cell Biol 17:299-313, 1963). Lines have been developed using several different strains of mice. Tissues are usually fibroblasts derived from mouse embryos but other types and sources have been developed as well. The 3T3 lines are valuable in vitro host systems for oncogenic virus transformation studies, since 3T3 cells possess a high sensitivity to CONTACT INHIBITION. 3T3 Cell,Cell, 3T3,Cells, 3T3

Related Publications

M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
December 2010, Animal reproduction science,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
April 2000, European journal of immunology,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
September 1996, Cancer research,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
January 2000, Journal of cellular physiology,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
August 2007, Molecular cancer therapeutics,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
July 1999, Endocrinology,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
August 2018, Experimental and therapeutic medicine,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
January 1995, Cancer research,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
May 2007, Leukemia,
M Resnicoff, and D Abraham, and W Yutanawiboonchai, and H L Rotman, and J Kajstura, and R Rubin, and P Zoltick, and R Baserga
May 2005, Journal of neuroscience research,
Copied contents to your clipboard!